Emerging biomarkers in inflammatory bowel disease (embark) study identifies fecal calprotectin, serum mmp9, and serum il-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging

William A. Faubion, Joel G. Fletcher, Sharon O'Byrne, Brian G. Feagan, Willem Js De Villiers, Bruce Salzberg, Scott Plevy, Deborah D. Proctor, John F. Valentine, Peter D. Higgins, Jeffrey M. Harris, Lauri Diehl, Lilyan Wright, Gaik Wei Tew, Diana Luca, Karen Basu, Mary E. Keir

Research output: Contribution to journalArticle

64 Scopus citations

Abstract

Objectives:In Crohn's disease (CD), clinical symptoms correspond poorly to inflammatory disease activity. Biomarkers reflective of mucosal and bowel wall inflammation would be useful to monitor disease activity. The EMBARK study evaluated disease activity in patients with ulcerative colitis (UC) and CD, and used endoscopy with or without cross-sectional imaging for biomarker discovery.Methods:UC (n=107) and CD (n=157) patients were characterized and underwent ileocolonoscopy (ICO). A subset of CD patients (n=66) also underwent computed tomography enterography (CTE). ICO and CTE were scored by a gastroenterologist and radiologist who incorporated findings of inflammation into a single score (ICO-CTE) for patients that underwent both procedures. Serum and fecal biomarkers were evaluated for association with the Mayo Clinic endoscopy score in UC patients and with ICO alone or ICO-CTE in CD patients. Individual biomarkers with a moderate degree of correlation (P≤0.3) were evaluated using multivariate analysis with model selection using a stepwise procedure.Results:In UC, ordinal logistic regression using Mayo Clinic endoscopy subscore selected the combination of fecal calprotectin and serum matrix metalloproteinase 9 (MMP9; pseudo R 2 =0.353). In CD, we found that use of the ICO-CTE increased specificity of known biomarkers. Using ICO-CTE as the dependent variable for biomarker discovery, the selected biomarkers were the combination of fecal calprotectin, serum MMP9, and serum IL-22 (r=0.699).Conclusions:Incorporation of both ICO and CTE into a single measure increased biomarker performance in CD. Combinations of fecal calprotectin and serum MMP9 for UC, and combinations of fecal calprotectin, serum MMP9, and serum interleukin-22 in CD, demonstrated the strongest association with imaging/endoscopy-defined inflammation.

Original languageEnglish (US)
Pages (from-to)1891-1900
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume108
Issue number12
DOIs
StatePublished - Dec 2013

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Emerging biomarkers in inflammatory bowel disease (embark) study identifies fecal calprotectin, serum mmp9, and serum il-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging'. Together they form a unique fingerprint.

  • Cite this

    Faubion, W. A., Fletcher, J. G., O'Byrne, S., Feagan, B. G., De Villiers, W. J., Salzberg, B., Plevy, S., Proctor, D. D., Valentine, J. F., Higgins, P. D., Harris, J. M., Diehl, L., Wright, L., Tew, G. W., Luca, D., Basu, K., & Keir, M. E. (2013). Emerging biomarkers in inflammatory bowel disease (embark) study identifies fecal calprotectin, serum mmp9, and serum il-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging. American Journal of Gastroenterology, 108(12), 1891-1900. https://doi.org/10.1038/ajg.2013.354